Sagimet Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
SGMT$10.89+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets (unaudited)
CONDENSED BALANCE SHEETS
(in thousands, except for share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · As of | ||||||
| · · September 30, · · December 31, | ||||||
| | 2024 | 2023 | ||||
| Assets | | | | | | |
| Current assets: · · | ||||||
| Cash and cash equivalents | | $77,014 | | $75,139 | ||
| Short-term marketable securities | | 75,472 | | 19,758 | ||
| Prepaid expenses and other current assets | | | 4,704 | | | 1,749 |
| Total current assets | | | 157,190 | | | 96,646 |
| Long-term marketable securities | | | 17,471 | | | — |
| Operating lease right-of-use assets | | | 114 | | | 73 |
| Total assets | | $174,775 | | $96,719 | ||
| Liabilities and stockholders’ equity | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $1,152 | | $186 | ||
| Accrued expenses and other current liabilities (includes nil and $31 payable to related parties as of September 30, 2024 and December 31, 2023, respectively) | | 2,824 | | 5,403 | ||
| Operating lease liabilities | | 116 | | 65 | ||
| Total current liabilities | | 4,092 | | 5,654 | ||
| Commitments and contingencies (Note 6) | | | ||||
| Stockholders’ equity: | | | ||||
| Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 | | | — | | | — |
| Series A common stock, $0.0001 per share: 500,000,000 shares authorized; 30,674,855 and 21,375,402 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | | | 3 | | | 2 |
| Series B common stock, $0.0001 per share: 15,000,000 shares authorized; 1,520,490 shares issued and outstanding at September 30, 2024 and December 31, 2023 | | | — | | | — |
| Additional paid-in capital | | 449,349 | | 340,777 | ||
| Accumulated deficit | | (279,110) | | (249,744) | ||
| Accumulated other comprehensive income | | 441 | | 30 | ||
| Total stockholders’ equity | | | 170,683 | | 91,065 | |
| Total liabilities and stockholders’ equity | | $174,775 | | $96,719 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.